atrasentan has been researched along with canagliflozin in 2 studies
| Studies (atrasentan) | Trials (atrasentan) | Recent Studies (post-2010) (atrasentan) | Studies (canagliflozin) | Trials (canagliflozin) | Recent Studies (post-2010) (canagliflozin) |
|---|---|---|---|---|---|
| 358 | 41 | 108 | 998 | 194 | 975 |
| Protein | Taxonomy | atrasentan (IC50) | canagliflozin (IC50) |
|---|---|---|---|
| Sodium/glucose cotransporter 1 | Homo sapiens (human) | 0.9497 | |
| Sodium/glucose cotransporter 2 | Homo sapiens (human) | 0.0039 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Breyer, MD; Susztak, K | 1 |
| Nangaku, M | 1 |
1 review(s) available for atrasentan and canagliflozin
| Article | Year |
|---|---|
Developing Treatments for Chronic Kidney Disease in the 21st Century.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Atrasentan; Benzhydryl Compounds; Canagliflozin; Diabetic Nephropathies; Drug Discovery; Endothelin Receptor Antagonists; Glucosides; Glycosaminoglycans; Humans; Hypoglycemic Agents; Mineralocorticoid Receptor Antagonists; Oleanolic Acid; Oxidative Stress; Pyridoxamine; Pyrrolidines; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
1 other study(ies) available for atrasentan and canagliflozin
| Article | Year |
|---|---|
Light of dawn in Melbourne: SONAR and CREDENCE.
Topics: Atrasentan; Australia; Canagliflozin; Clinical Trials as Topic; Congresses as Topic; Diabetic Nephropathies; Disease Progression; Endothelin A Receptor Antagonists; Humans; Kidney Failure, Chronic; Nephrology; Societies, Medical; Sodium-Glucose Transporter 2 Inhibitors | 2019 |